US Pharma MarketingASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it?
ASCO: Sac-TMT’s massive phase 3 program has a jarring gap. Does Merck plan to close it? is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already includes 17 global phase 3 trials. But there’s one important missing piece.
Source: FiercePharma